+352 464 010 600
No fees for performance
No up front fees
No debt or derivatives
No market timing
No index hugging
Understand more of what we are trying to achieve
Download the Owners Manual
Sign up for email alerts
Fundsmith Annual Shareholders' Meeting 2017
24 April 2017
ASM 2016 - Should you buy bonds?
22 March 2016
ASM 2016 - Are we in a bear market?
21 March 2016
View all Fundsmith TV
What we are saying
Fundsmith Equity Fund Wins Three Awards – AJ Bell, Financial News and Investors Chronicle
December 01 2017
The Fundsmith Equity Fund has won the Global Equity category at AJ Bell’s inaugural Fund and Investment Trust awards, has been named Boutique Manager of the Year at the Financial News awards and has won the award for the Best Unit Trust at Investors Chronicle 2017 Awards.
Fundsmith launches Sustainable Equity Fund
November 01 2017
Fundsmith LLP is pleased to announce the launch of a new institutional fund, the Fundsmith Sustainable Equity Fund, on 1st November 2017.
What others are saying
This is Money - Why investors can't get enough of Fundsmith: How City veteran Terry Smith took Buffett-style investing to the top of the fund charts
January 22 2018
Fundsmith has developed a considerable fan club of investors and it is not difficult to see why. The Fundsmith Equity fund topped the bestseller lists of both the Bestinvest and AJ Bell DIY investment platforms last year and has returned a whopping 266 per cent in a little over seven years since it was launched.
The Guardian – Terry Smith – the man who beat the market in 2017
December 30 2017
Terry Smith has emerged as Britain’s top investment performer once again after another year of stellar returns.
What Terry Smith is saying
Financial Times – ESG? SRI? Is your green portfolio really green?
January 18 2018
In his article for FTfm, Terry Smith discusses sustainable investing and questions how green your portfolio really is.
Financial Times – AstraZeneca is beginning to look like Tesco
August 04 2017
In his latest article for FT Money, Terry Smith believes that AstraZeneca’s problems go much deeper than its recent setback for a single drug.
See all news